ASCENT-03
1L mTNBC (PD-(L)1-ineligible)
Sacituzumab Govitecan
ASCENT-04
1L PD-L1+ mTNBC (CPS≥10)
Sacituzumab Govitecan + Pembrolizumab
DESTINY-Breast03
2L HER2+ mBC
T-DXd
DESTINY-Breast05
Adjuvant HER2+ BC
T-DXd
DESTINY-Breast06
HR+/HER2-low mBC
T-DXd
DESTINY-Breast09
1L HER2+ mBC
T-DXd + Pertuzumab
DESTINY-Breast11
Neoadjuvant HR HER2+ eBC
T-DXd (Enhertu)
EMBER-3
ER+/HER2- advanced BC
Imlunestrant
EMERALD
HR+/HER2- mBC (ESR1m)
Elacestrant
EVERA
ER+/HER2- mBC
Giredestrant + Everolimus
GeparDouze
TNBC neoadjuvant
Atezolizumab + chemo
HER2CLIMB-05
HER2+ mBC brain mets
Tucatinib
I-SPY 2.2
Neoadjuvant platform
Multiple agents
INAVO120
PIK3CA+ HR+/HER2- mBC
Inavolisib
INNOVATION
HER2+ gastric/breast
Trastuzumab + chemo
KEYNOTE-522
Neoadjuvant TNBC
Pembrolizumab + chemo
NATALEE
Adjuvant HR+/HER2- BC
Ribociclib
OPTIMA
Adjuvant high-risk ER+/HER2- early BC
Prosigna PAM50 ROR-directed chemo
PADMA
HR+/HER2- mBC
CDK4/6 + endocrine
PANKU-Breast01
HR+/HER2- advanced BC
Iza-bren (EGFR×HER3 ADC)
PANKU-Breast02
2L+ metastatic TNBC (post-taxane)
Iza-bren (EGFR×HER3 ADC)
PATINA
HR+/HER2+ mBC
Palbociclib + anti-HER2
SERENA-4
1L ER+/HER2- aBC — PFS endpoint not met
Camizestrant + palbociclib
SERENA-6
HR+/HER2- mBC (ESR1m)
Camizestrant
SoltiVALENTINE
HR+/HER2- mBC
Novel
TROPION-Breast01
HR+/HER2- mBC
Datopotamab deruxtecan
TROPiCS-04
Pretreated mUC (post-platinum, post-IO)
Sacituzumab govitecan
VERITAC-2
HR+/HER2- mBC
Vepdegestrant
VIKTORIA-1
HR+/HER2- mBC
Camizestrant + Everolimus
ZEST
Early BC (ctDNA MRD)
Niraparib
lidERA
Adjuvant HR+/HER2- BC
Giredestrant
postMONARCH
HR+/HER2- post-CDK4/6 mBC
Abemaciclib rechallenge
ALASCCA
CRC (aspirin adjuvant)
Aspirin
BESPOKE
CRC (ctDNA MRD)
Signatera guided
BREAKWATER
BRAF V600E mCRC (1L)
Enco + Cetux + mFOLFOX6
ATOMIC
Adjuvant dMMR/MSI-H Stage III colon cancer
FOLFOX ± atezolizumab
RMC-9805-001
2L/3L+ RAS G12D metastatic PDAC
Zoldonrasib + daraxonrasib
EMERALD-1
Embolization-eligible HCC
Durvalumab + TACE
EMERALD-3
Embolization-eligible HCC
STRIDE ± lenvatinib + TACE
GLEAM
CLDN18.2+ metastatic pancreatic cancer
Zolbetuximab + gem/nab-paclitaxel
COLLISION
Resectable colorectal liver mets
Surgery vs ablation
COMMIT
1L dMMR/MSI-H mCRC
Atezo + FOLFOX + bev
CRITICS-II
Resectable gastric (preoperative)
CT vs CT+CRT vs CRT
KRYSTAL-10
2L KRAS G12C mCRC — CRC accelerated approval withdrawn Sept 1, 2026
Adagrasib (Krazati) + cetuximab vs chemo · Bristol Myers Squibb
REFOCUS
Previously treated FGFR2 fusion/rearrangement cholangiocarcinoma — FDA approved Sept 23, 2026
Lirafugratinib (Lyrfigtu) · Elevar Therapeutics
HARMONi-GI1
1L advanced biliary tract cancer, China (LBA8)
Ivonescimab + gem/cis vs durvalumab + gem/cis · investigational
CLARITY-Gastric01
Previously treated CLDN18.2+ gastric/GEJ cancer (LBA7)
Sonesitatug vedotin (Sone-Ve) vs investigator’s choice · AstraZeneca · investigational
SANO
Oesophageal cancer, clinical complete response after nCRT — 5-year results (LBA78)
Active surveillance vs oesophagectomy · Erasmus MC
RASolute 302
2L Metastatic PDAC (RAS-mutant)
Daraxonrasib (RMC-6236) vs chemo · Revolution Medicines
CodeBreaK 300
KRAS G12C mCRC
Sotorasib + panitumumab
DESTINY-Gastric04
2L HER2+ gastric/GEJ
T-DXd
DYNAMIC-III
Stage III colon (ctDNA-guided adj)
ctDNA strategy
ESOPEC
Resectable esophageal adeno
FLOT vs CROSS
LIBRETTO-432
Adjuvant resected stage IB–IIIA RET+ NSCLC
Selpercatinib (Retevmo) · Eli Lilly
ALKOVE-1
TKI-pretreated ALK+ NSCLC
Neladalkib (NVL-655) · Nuvalent
WU-KONG28
1L EGFR exon20ins NSCLC
Sunvozertinib (Zegfrovy)
TRITON
1L NSQ NSCLC (STK11 / KEAP1 / KRAS)
Tremelimumab + Durvalumab + Chemo (Imjudo / Imfinzi)
HARMONi-6
1L Advanced Squamous NSCLC
Ivonescimab + chemo vs Tislelizumab + chemo · Akeso / Summit
SARC041
Advanced Dedifferentiated Liposarcoma (DDLPS)
Abemaciclib (Verzenio) · CDK4/6i
PAPILLON
1L EGFR exon20ins NSCLC
Amivantamab + chemo
OptiTROP-Lung05
1L PD-L1+ NSCLC
Sac-TMT (SKB264) + pembrolizumab · Kelun/Merck
POTOMAC
BCG-naïve High-Risk NMIBC · FDA Approved
Durvalumab + BCG · AstraZeneca
AcceleRET-Lung
1L RET-fusion+ NSCLC
Pralsetinib (GAVRETO) · Rigel
MAJESTEC-9
1–3L RRMM · NEJM · Practice-Changing
Teclistamab (Tecvayli) · Johnson & Johnson
SUCCESSOR-2
RRMM · First CELMoD Phase 3 Win · LBA
Mezigdomide + Kd · Bristol Myers Squibb
KEYNOTE-564
Adjuvant High-Risk ccRCC · ctDNA Update
Pembrolizumab (Keytruda) · Merck
HERIZON-GEA-01
1L HER2+ gastric/GEJ
Zanidatamab + chemo
ILUSTRO
CLDN18.2+ gastric/GEJ
Zolbetuximab triplet
KEYNOTE-937
Adjuvant HCC
Pembrolizumab
PANGEA-2
HER2+ gastric/GEJ
Targeted-platform
TRANSMET
Unresectable colorectal liver mets
Liver transplant
CLEAR
1L advanced RCC
Lenvatinib + Pembro
CheckMate-274
Adjuvant high-risk MIUC
Nivolumab
CheckMate-8HW
MSI-H/dMMR mCRC
Nivo + Ipi
CheckMate-901
1L mUC cisplatin-eligible
Nivo + gem/cis
CheckMate-9DW
1L uHCC
Nivo + Ipi
CheckMate-9ER
1L advanced RCC
Nivo + Cabozantinib
EV-302
1L mUC bladder
Enfortumab + Pembro
KEYNOTE-361
1L mUC bladder
Pembro ± chemo
KEYNOTE-B15
Perioperative cis-eligible MIBC
EV + Pembro
KEYNOTE-905
Perioperative cis-ineligible MIBC
EV + Pembro
ENERGIZE (CA017-078)
Perioperative MIBC
Nivolumab + GC
KEYNOTE-866
Perioperative cis-eligible MIBC
Pembro + GC
DASL-HiCaP
Very high-risk localised prostate cancer (LBA4)
Darolutamide + ADT + RT · investigational
LITESPARK-011
Advanced RCC w/ clear cell component, post PD-(L)1
Belzutifan + Lenvatinib
LITESPARK-012
1L advanced clear-cell RCC (3586O)
Belzutifan or quavonlimab triplet vs pembro + lenvatinib · investigational
LITESPARK-022
Adjuvant ccRCC post-nephrectomy
Belzutifan + Pembro
LiteSpark-003
Advanced ccRCC
Belzutifan
NIAGARA
Perioperative MIBC
Durvalumab + GC
PEACE-3
mCRPC with bone mets
Enza + Radium-223
TalaPro-2
1L mCRPC (HRR+)
Talazoparib + Enza
TALAPRO-3
HRR gene-mutated mAPMN/S prostate cancer — FDA approved Oct 26, 2026
Talazoparib (Talzenna) + enzalutamide · rPFS HR 0.48; OS immature
PSMAddition
PSMA+ mHSPC (mAPMN/S)
Pluvicto + ADT + ARPI
TopGear
Resectable gastric
Preoperative chemoradiation
ADAURA
Adjuvant EGFR-mutant NSCLC
Osimertinib
ARROS-1
ROS1+ NSCLC (2L+, prior TKI)
Zidesamtinib (Jideytro)
ADEPPT
EGFR-mutant NSCLC (ELCC26)
Novel targeted
ADRIATIC
Limited-stage SCLC
Durvalumab
AEGEAN
Perioperative resectable NSCLC
Durvalumab + chemo
ALINA
Adjuvant ALK+ NSCLC
Alectinib
ASTEROID
NSCLC (ELCC26)
Novel targeted
BEAMION-LUNG-1
HER2-mutant NSCLC
Zongertinib
BECOME
NSCLC (ELCC26)
Novel targeted
CHRYSALIS-2
EGFR-mutant NSCLC (post-osimertinib)
Ami + Laz
CROWN
1L ALK+ NSCLC
Lorlatinib
SigVie-002
2L+ Non-Squamous NSCLC (LBA68 · OS not met)
Sigvotatug vedotin vs docetaxel · investigational
CAPItello-281
PTEN-deficient mHSPC (mAPMN/S)
Capivasertib + Abiraterone
CheckMate-77T
Perioperative NSCLC
Nivolumab + chemo
DELLPHI-304
SCLC
Tarlatamab
EVOKE-01
Post-platinum NSCLC
Sacituzumab govitecan
FLAURA
1L EGFR-mutant NSCLC
Osimertinib
FLAURA2
1L EGFR-mutant NSCLC
Osimertinib + chemo
HARMONi
EGFR-mutant NSCLC
Ivonescimab
HARMONi-2
1L PD-L1+ NSCLC
Ivonescimab
PANKU-Lung01
EGFRm non-squamous NSCLC after 3rd-gen EGFR TKI, China (LBA71)
Iza-bren vs platinum-pemetrexed · investigational
OptiTROP-Lung04
EGFR-mutant NSCLC after EGFR-TKI, China (LBA67 final OS)
Sac-TMT vs pemetrexed + platinum · approved in China, not FDA
HERON-Lung01
EGFR-mutant NSCLC after EGFR-TKI, China (LBA72)
Ruzaltatug rezetecan (HER3 ADC) vs platinum-pemetrexed · investigational
SANOVO
1L EGFR-mutant, MET-overexpressing NSCLC, China (LBA69)
Savolitinib + osimertinib vs osimertinib · 1L investigational
Dalmelitinib + Aumolertinib (HS-10241-301)
EGFR-mutant, MET-amplified NSCLC after EGFR-TKI, China (2615O)
Dalmelitinib + aumolertinib vs platinum-pemetrexed · investigational
Neotorch
Resectable stage II–III NSCLC, perioperative (LBA64 final)
Toripalimab + chemo vs placebo + chemo · approved in China (IIIA–IIIB), not FDA/EMA for NSCLC
ASTRIDE
1L extensive-stage SCLC, US bridging trial (3809O)
Serplulimab vs atezolizumab + carboplatin-etoposide · not FDA approved
PEARLS / KEYNOTE-091
Resected stage IB–IIIA NSCLC, adjuvant (2511O final analysis)
Pembrolizumab vs placebo · FDA/EU approved after platinum chemo
OptiTROP-Lung06
1L PD-L1-negative nonsquamous NSCLC, China (LBA66)
Sac-TMT + pembrolizumab vs chemo + pembrolizumab · investigational
SARON
Synchronous oligometastatic driver-negative NSCLC (2613O)
Systemic therapy + consolidation RT/SABR vs systemic therapy · radiotherapy strategy, phase II
PERSEE
1L NSCLC, PD-L1 ≥50% (2614O)
Pembrolizumab + chemo vs pembrolizumab alone · both FDA-approved options
HARMONi-A
EGFR-mutant NSCLC (Asia)
Ivonescimab
KEYNOTE-671
Perioperative NSCLC
Pembrolizumab + chemo
RMC-6236-001 (NSCLC)
2L+ RAS-Mutant NSCLC
Daraxonrasib (RASONQUE)
KRYSTAL-12
KRAS G12C NSCLC
Adagrasib
LAURA
Post-CRT stage III EGFR+ NSCLC
Osimertinib
LUNAR
Post-platinum NSCLC (TTFields)
TTFields + SoC
KRASCENDO-1
Previously treated advanced KRAS G12C+ NSCLC · Ph3 topline: PFS + OS met
Divarasib vs sotorasib/adagrasib
NAUTIKA1 · KRAS G12C
Resectable KRAS G12C+ NSCLC · umbrella cohort
Neoadjuvant divarasib
NAUTIKA1 · ALK
Resectable ALK+ NSCLC · MO06.01 primary analysis
Neoadjuvant alectinib
TAISHAN-302
Relapsed SCLC (2L) · OS 13.3 vs 9.4 mo · WCLC26/NEJM
Tam-Peli (B7-H3 ADC) vs topotecan
ARTEMIS-008
Relapsed SCLC · OS 18.5 mo, HR 0.46 · first B7-H3 ADC Ph3 OS win
Ris-Rez (B7-H3 ADC) vs topotecan
MAVERICK (SWOG S1827)
SCLC · MRI surveillance vs PCI · preliminary OS non-inferior
MRI surveillance ± PCI
EVOKE-03 / KEYNOTE-D46
1L PD-L1≥50% mNSCLC · endpoints not met · discontinued
Sacituzumab govitecan + pembrolizumab
MDT-BRIDGE
Resectable/borderline IIB–IIIB NSCLC · resection 74.6%, pCR 27.3%
Neoadjuvant durvalumab + chemo
IMpower030
Resectable II–IIIB NSCLC · EFS threshold not met · pCR 29.6% vs 8.5%
Perioperative atezolizumab
MARIPOSA
1L EGFR-mutant NSCLC
Amivantamab + Lazertinib
METIS
NSCLC brain mets (TTFields)
TTFields
OptiTROP-Lung03
NSCLC (ELCC26)
Sacituzumab tirumotecan
PALOMA-3
EGFR+ NSCLC (subcutaneous)
Amivantamab SC
PRESERVE-003
Perioperative NSCLC (ELCC26)
Novel targeted
SOHO-01
1L + 2L HER2-mutant NSCLC (FDA approved)
Sevabertinib (Hyrnuo)
IMforte
1L maintenance ES-SCLC (FDA approved)
Lurbinectedin + atezolizumab
DeLLphi-305
1L maintenance ES-SCLC
Tarlatamab + durvalumab
SAFFRON
MET-driven EGFRm NSCLC post-osi
Savolitinib + osimertinib
SAVANNAH
EGFRm MET+ NSCLC post-osi (Ph2)
Savolitinib + osimertinib
DESTINY-Lung04
1L HER2-mutant NSCLC
T-DXd (Enhertu)
OrigAMI-4
R/M head and neck SCC after platinum + anti-PD-(L)1
Amivantamab SC (Rybrevant Faspro) · FDA accelerated approval
INTerpath-001
Adjuvant resected melanoma
Intismeran + pembrolizumab
IGNYTE
Anti-PD-1-failed melanoma
RP1 (TUDRIQEV) + nivolumab
IGNYTE-3
Post PD-1/CTLA-4 melanoma (Ph3 confirmatory)
RP1 + nivo vs physician's choice
NADINA
Resectable macroscopic stage III melanoma — 3-year update (2076RO)
Neoadjuvant ipi + nivo vs adjuvant nivolumab
NHS-Galleri
MCED screening RCT, 142,000+ UK adults
Galleri MCED blood test (GRAIL)
PATHFINDER-2
MCED screening, single-arm registrational
Galleri MCED blood test (GRAIL)
ARTEMIS-011
Relapsed/refractory osteosarcoma, China (LBA9)
Risvutatug rezetecan (Ris-Rez, B7-H3 ADC) vs gemcitabine + docetaxel · investigational
MOIO
Advanced solid tumors responding to immunotherapy at 6 months (LBA10)
Same-dose ICI every 12 weeks vs standard · stopped early, non-inferiority not shown
TroFuse-005
Endometrial cancer after platinum and immunotherapy (LBA11)
Sac-TMT vs chemotherapy · OS 19.0 vs 12.1 mo (HR 0.68); investigational, FDA priority review
KEYNOTE-C93
1L dMMR advanced or recurrent endometrial cancer (LBA12)
Pembrolizumab alone vs carboplatin-paclitaxel · PFS met, OS not met at interim; investigational
REZILIENT3
1L EGFR exon20ins NSCLC
Zipalertinib + chemo
SKYSCRAPER-01
1L PD-L1+ NSCLC
Tiragolumab + atezo
TOP Study
NSCLC (ELCC26)
Biomarker-driven
i-TIMES
NSCLC (ELCC26)
Novel targeted
AQUILA
Smoldering MM
Daratumumab
AURIGA
Post-transplant maintenance
Daratumumab + Len
CAR-PRISM
High-risk NDMM
CAR-T front-line
CARTITUDE-2
1-3 prior lines
Cilta-cel
CARTITUDE-4
Len-refractory MM
Cilta-cel
CARTITUDE-6
NDMM transplant-eligible
Cilta-cel front-line
CASSIOPEIA
Transplant-eligible NDMM
Dara-VTd
MonumenTAL-3
Relapsed/refractory MM
Talquetamab + Dara ± Pom
MonumenTAL-6
R/R myeloma, 1-4 prior lines
Teclistamab + Talquetamab
CEPHEUS
Transplant-ineligible NDMM
Dara-VRd
DREAMM-7
RRMM post-1 line
Belantamab + Vd
DREAMM-8
RRMM (len-exposed)
Belantamab + Pd
DREAMM-9
NDMM transplant-ineligible
Belantamab + VRd
GMMG-HD6
NDMM transplant-eligible
Elo + VRd
GMMG-HD7
NDMM transplant-eligible
Isa-VRd induction
CERVINO
Triple-class exposed R/R MM
Etentamig (ABBV-383)
EXCALIBER-RRMM
R/R MM, 1-2 prior lines
Iberdomide (Zenbexus)
IsKia
Transplant-eligible NDMM
Isa-KRd
KarMMa-3
RRMM (2-4 prior lines)
Ide-cel
MajesTEC-4
Post-transplant maintenance
Teclistamab
MajesTEC-5
NDMM transplant-eligible
Tec + DRd
MAIA
Transplant-ineligible NDMM
D-Rd (daratumumab)
PERSEUS
Transplant-eligible NDMM
D-VRd
ENDURANCE
Standard-risk NDMM (transplant-deferred)
Lenalidomide maintenance duration
iMMagine-1
RRMM
Anito-cel (BCMA CAR-T)
ImmunoPRISM
High-risk smoldering MM · randomized Ph2 · Nature Medicine
Teclistamab vs Rd
3082CL0101
Solid tumors
Novel agent
ABRAVE
Oncology
-
ACCELERATE
Oncology
-
ANDROMEDA
Oncology
-
ARMANI
Oncology
-
BLB01D1
Solid tumors
BL-B01D1 ADC
CABINET
Neuroendocrine tumors
Cabozantinib
CALYPSO
Oncology
-
EUROPA
Oncology
-
EXALT-3
Oncology
Functional precision
JS001-SC
Oncology
Toripalimab SC
KANDLELIT-001
Solid tumors
Novel agent
LATIFY
Oncology
-
NCT05879978
Solid tumors
Novel agent
NORTHSTAR
Oncology
-
SACItuzumab-IO
Oncology
Sacituzumab + IO
SUPREMO
Oncology
-
StarterNET
NETs
-
YL202
Solid tumors
Novel ADC
ARC-20
Advanced ccRCC
Casdatifan (HIF-2α)
CAPItello-291
HR+/HER2- mBC, AKT-altered
Capivasertib + Fulvestrant
HER2CLIMB-02
HER2+ metastatic BC
Tucatinib + T-DM1
HORIZON-Breast01
HER2+ metastatic BC
Trastuzumab rezetecan
HORIZON-Breast06
HER2-low advanced BC (LBA13)
Trastuzumab rezetecan vs chemo · investigational
IMvigor011
Adjuvant MIBC, ctDNA MRD+
Atezolizumab (Tecentriq)
IRAKLIA
R/R + newly diagnosed myeloma
SubQ Isatuximab (Sarclisa)
KarMMa
Relapsed/refractory myeloma
Ide-cel (Abecma)
MajesTEC-3
Relapsed/refractory myeloma
Teclistamab + Daratumumab
MARIPOSA-2
EGFR NSCLC 2L post-osimertinib
Amivantamab + Lazertinib + chemo
PERSEVERA
1L ER+/HER2- advanced BC
Giredestrant + Palbociclib
PHERGain
HER2+ early BC, chemo-free
Trastuzumab + Pertuzumab
PHERGain-2
HER2+ early BC, chemo-free
Trastuzumab + Pertuzumab
PRECOOPERA
Premenopausal ER+/HER2- early BC
Giredestrant ± Triptorelin
PROTEUS
High-risk localized prostate cancer
Apalutamide (Erleada) + ADT
Pumitamig (BNT327)
Metastatic TNBC
PD-L1 × VEGF-A bispecific
RedirecTT-1
Relapsed/refractory myeloma
Talquetamab + Teclistamab
IMROZ
Transplant-ineligible NDMM
Isa-VRd (Sarclisa)
MIDAS
Transplant-eligible NDMM
Isa-KRd · MRD-adapted
SATEEN
HER2+ metastatic BC
Sacituzumab govitecan + Trastuzumab
TALENT
HR+/HER2-low early BC (LBA23)
Neoadjuvant T-DXd ± anastrozole or → TC · investigational
KEYNOTE-B49
PD-L1+ HR+/HER2− advanced BC (LBA51)
Pembrolizumab vs placebo, each + chemo · investigational
OptiTROP-Breast01
Previously treated metastatic TNBC (4639RO final OS)
Sac-TMT vs chemotherapy · approved in China, investigational in US
SWITCH
HER2-negative MBC after a prior ADC (4RO, phase 2 platform)
Four Hengrui TOP1i ADCs (HER2/TROP2/HER3/Nectin-4) · investigational
BRIDGET
HER2+ MBC with isolated brain progression (1767RO)
Tucatinib + trastuzumab/pertuzumab or T-DM1 · investigational as tested
TRAIN-4
HR+/HER2+ early BC
Trastuzumab + Pertuzumab
TRAK-ER
HR+/HER2- early BC, ctDNA-guided
Fulvestrant + Palbociclib
TROPION-Breast02
1L metastatic TNBC
Datopotamab deruxtecan (Datroway)
VOLGA
Cisplatin-ineligible MIBC
Durvalumab + EV ± Tremelimumab
WU-KONG1B
EGFR Exon20ins NSCLC, 2L+
Sunvozertinib (Zegfrovy)